IL139071A0 - A composition containing an aldose reduction inhibitor for treatment of external secretion disorders - Google Patents

A composition containing an aldose reduction inhibitor for treatment of external secretion disorders

Info

Publication number
IL139071A0
IL139071A0 IL13907100A IL13907100A IL139071A0 IL 139071 A0 IL139071 A0 IL 139071A0 IL 13907100 A IL13907100 A IL 13907100A IL 13907100 A IL13907100 A IL 13907100A IL 139071 A0 IL139071 A0 IL 139071A0
Authority
IL
Israel
Prior art keywords
treatment
composition containing
reduction inhibitor
secretion disorders
external secretion
Prior art date
Application number
IL13907100A
Other languages
English (en)
Original Assignee
R Tech Ueno Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by R Tech Ueno Ltd filed Critical R Tech Ueno Ltd
Publication of IL139071A0 publication Critical patent/IL139071A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL13907100A 1999-02-18 2000-02-15 A composition containing an aldose reduction inhibitor for treatment of external secretion disorders IL139071A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12072599P 1999-02-18 1999-02-18
PCT/JP2000/000810 WO2000048447A2 (en) 1999-02-18 2000-02-15 Composition for treatment of external secretion disorders except hypolacrimation

Publications (1)

Publication Number Publication Date
IL139071A0 true IL139071A0 (en) 2001-11-25

Family

ID=22392173

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13907100A IL139071A0 (en) 1999-02-18 2000-02-15 A composition containing an aldose reduction inhibitor for treatment of external secretion disorders

Country Status (11)

Country Link
US (1) US6339088B1 (xx)
EP (1) EP1073666A1 (xx)
JP (1) JP2003516309A (xx)
AR (1) AR029335A1 (xx)
AU (1) AU2462400A (xx)
BR (1) BR0005010A (xx)
CA (1) CA2328877A1 (xx)
IL (1) IL139071A0 (xx)
MX (1) MXPA00010193A (xx)
NO (1) NO20005216D0 (xx)
WO (1) WO2000048447A2 (xx)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6555540B1 (en) * 1999-06-30 2003-04-29 Pfizer Inc Combinations of aldose reductase inhibitors and selective cyclooxygenase-2 inhibitors
JP2002265375A (ja) * 2001-03-13 2002-09-18 Inabata Koryo Kk 唾液分泌促進剤及びこれを含有した食品組成物並びに口腔用組成物
AU2003243603A1 (en) * 2002-06-13 2003-12-31 Board Of Regents, The University Of Texas System Methods and compositions involving aldose reductase inhibitors
WO2006013914A1 (ja) * 2004-08-06 2006-02-09 Daiichi Pharmaceutical Co., Ltd. 口腔粘膜投与剤
US20110092566A1 (en) * 2004-11-19 2011-04-21 Srivastava Satish K Treatment of cancer with aldose reductase inhibitors
EP2848252A3 (en) 2007-03-23 2015-06-17 The Board of Regents of the University of Texas System Aldose reductase inhibitors for use in treating uveitis
US20090270490A1 (en) * 2008-04-24 2009-10-29 The Board Of Regents Of The University Of Texas System Methods involving aldose reductase inhibition
ITUB20152695A1 (it) * 2015-07-31 2017-01-31 Metis Healthcare S R L Composizione per l'aumento delle secrezioni umorali

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8524663D0 (en) * 1985-10-07 1985-11-13 Fujisawa Pharmaceutical Co Quinazoline derivatives
US4931440A (en) * 1987-07-29 1990-06-05 Fujisawa Pharmaceutical Company, Ltd. Uricosuric composition
JP2621460B2 (ja) * 1988-02-29 1997-06-18 藤沢薬品工業株式会社 利尿または降圧剤
DE69924493T2 (de) * 1998-07-02 2005-09-15 Neurosearch A/S Kaliumkanal-blockierende mittel
WO2000043015A1 (fr) * 1999-01-25 2000-07-27 Fujisawa Pharmaceutical Co., Ltd. Gouttes ophtalmologiques

Also Published As

Publication number Publication date
WO2000048447A3 (en) 2001-01-25
WO2000048447A2 (en) 2000-08-24
BR0005010A (pt) 2002-03-19
EP1073666A1 (en) 2001-02-07
MXPA00010193A (es) 2002-04-17
AR029335A1 (es) 2003-06-25
CA2328877A1 (en) 2000-08-24
US6339088B1 (en) 2002-01-15
NO20005216D0 (no) 2000-10-17
AU2462400A (en) 2000-09-04
JP2003516309A (ja) 2003-05-13

Similar Documents

Publication Publication Date Title
IL147440A0 (en) Composition for treatment of external secretion disorders
PL351134A1 (en) Compositions for treatment of disorders of the oesophagus
SI1423381T1 (sl) Inhibitorji 17-beta-hidroksisteroidne dehidrogenaze tipa 3 za zdravljenje androgensko odvisnih bolezni
AU147234S (en) A set of bandage frames
IL160630A0 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
IL160648A0 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
GB9922554D0 (en) Inhibition of secretion from non-neuronal cells
GB0007193D0 (en) Treatment of movrmrnt disorders
HUP0201393A3 (en) Use of xenon for treating neurointoxications
IL138129A (en) Composition for therapy of estrogen-associated disorders
AU2001233081A1 (en) Composition for treatment of stress
IL127496A0 (en) The use of MMP inhibitors for the treatment of ocular angiogenesis
GB9900227D0 (en) Use of a composition
IL139071A0 (en) A composition containing an aldose reduction inhibitor for treatment of external secretion disorders
HUP0302430A3 (en) Use of 1-phenyl-3-dimethylaminopropane compounds for treating urinary incontience
HRP20020729A2 (en) Treatment of psoriasis
IL147363A0 (en) Ppar delta inhibitor for the treatment of cardiovascular diseases
IL131047A0 (en) Use of il-18 inhibitors
GB2355657B (en) Inhibitors Of Gastric Acid Secretion
AU2003239025A1 (en) Combination of an acid secretion inhibiting agent and a reflux inhibitor for the treatment of gerd
HUP0303268A3 (en) Use of substituted 6-dimethylaminomethyl-1-phenyl-cyclohexane compounds for treating urinary incontinence
SI1468686T1 (sl) S-metil-dihidro-ziprazidon za zdravljenje psihiatricnih motenj
HK1043938A1 (en) Composition for the treatment of psoriasis
GB9909133D0 (en) Inhibition of endopeptidase by cystatins
PL355625A1 (en) Use of formulations for treating surfaces for temporarily improving dirt-removing behavior